Cogent Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $20.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sam Slutsky has given his Buy rating due to a combination of factors including the promising developments in Cogent Biosciences’ pipeline. The company recently announced positive results from its SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis, and plans to file an NDA later this year. Additionally, upcoming data readouts for bezuclastinib in advanced systemic mastocytosis and second-line gastrointestinal stromal tumors are anticipated to be positive, potentially unlocking significant market opportunities.
Furthermore, Cogent Biosciences has a strong financial position, with substantial cash reserves and additional funding secured through a public offering and a debt financing facility. This financial stability is expected to support the company’s operations through the anticipated commercial launch and into 2027. The combination of promising clinical developments and a solid financial foundation underpins Slutsky’s optimistic outlook for Cogent Biosciences.
In another report released on July 28, Piper Sandler also maintained a Buy rating on the stock with a $24.00 price target.